Skip to main content

Table 4 Sleep actigraphy data

From: Palmitoylethanolamide for sleep disturbance. A double-blind, randomised, placebo-controlled interventional study

  PEA Placebo
Baseline Week 4 Week 8 Baseline Week 4 Week 8
Total Sleep time (hrs) 7.49 ± 1.1 7.66 ± 1.2 7.58 ± 1.1 7.52 ± 1.2 7.54 ± 1.2 7.48 ± 1.1
Sleep Time (hrs) 7.00 ± 1.0 7.10 ± 1.0 7.03 ± 1.1 6.98 ± 1.2 7.02 ± 1.2 6.97 ± 1.1
Interruptions (min) 34.3 ± 14.1 32.3 ± 11.6 32.2 ± 11.2 32.1 ± 12.2 31.3 ± 12.4 30.9 ± 11.8
Sleep quality (1–5) 2.7 ± 0.6 3.1 ± 0.7 3.1 ± 0.7 2.5 ± 0.7 3.0 ± 0.7 2.9 ± 0.9
Sleep Continuity (1–5) 3.2 ± 0.9 3.2 ± 0.9 3.2 ± 0.9 3.2 ± 0.9 3.4 ± 1.0 3.3 ± 0.9
Sleep Percentage (%) 92.4 ± 3.9 92.9 ± 3.0 92.8 ± 2.4 92.8 ± 3.0 91.1 ± 7.5 93.0 ± 2.9
  1. N.B. Data presented as mean ± standard deviation; total sleep time = sleep time + interruptions + sleep latency; PEA palmitoylethanolamide